Navigation Links
Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C
Date:4/17/2011

etitive market positioning and the commercial opportunity for AMR101, including the number of patients that could potentially benefit from AMR101, and the timing of data publication. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein are the following: anticipated operating losses and the likely need for additional capital to fund future operations; uncertainties associated generally with research and development, clinical trials and related regulatory approvals; the risk that SPAs are not a guarantee that FDA will accept an NDA or approve a product candidate upon submission; uncertainties relating to the further analysis of the ANCHOR and MARINE trials; dependence on third-party manufacturers, suppliers and collaborators; significant competition; loss of key personnel; and uncertainties associated with market acceptance and adequacy of reimbursement, technological change and government regulation. A further list and description of these risks, uncertainties and other matters can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K.  Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Investor Contact Information:
Stephen D. Schultz
Investor Relations and Corporate Communications
Amarin Corporation
In U.S.: +1 (860) 572-4979 x292
investor.relations@amarincorp.com

Lee M. Stern
The Trout Group
In U.S.: +1 (646) 378-292
'/>"/>

SOURCE Amarin Corporation plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
4. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
5. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
8. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... the Netherlands , May 5, 2015 ... lower esophageal sphincter (LES) stimulation therapy for gastroesophageal ... and efficacy results. The results demonstrated an excellent ... regurgitation and the "gold-standard" esophageal acid exposure (measured ... of dependence on daily PPI medications. ...
(Date:5/5/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/9pthtm/home_healthcare ) has ... Market - Forecast to 2020" report to their ... to reach more than $300+ billion growing at a ... equipment market is expected to grow at a faster ... is gaining a tremendous attention over hospitals for the ...
(Date:5/5/2015)... Calif., May 5, 2015 Isis Pharmaceuticals, Inc. ... income of $4.0 million for the three months ended ... operating loss of $22.6 million for the same period ... to higher revenue from milestone payments earned from its ... a GAAP basis, Isis reported a loss from operations ...
Breaking Medicine Technology:Excellent three year results of EndoStim therapy for severe reflux disease presented at the SAGES Annual Meeting in Nashville. 2Excellent three year results of EndoStim therapy for severe reflux disease presented at the SAGES Annual Meeting in Nashville. 3Global Home Healthcare Global Market 2015 - Forecast to 2020 for the $300 Billion Market 2Isis Reports Financial Results and Highlights for First Quarter 2015 2Isis Reports Financial Results and Highlights for First Quarter 2015 3Isis Reports Financial Results and Highlights for First Quarter 2015 4Isis Reports Financial Results and Highlights for First Quarter 2015 5Isis Reports Financial Results and Highlights for First Quarter 2015 6Isis Reports Financial Results and Highlights for First Quarter 2015 7Isis Reports Financial Results and Highlights for First Quarter 2015 8Isis Reports Financial Results and Highlights for First Quarter 2015 9Isis Reports Financial Results and Highlights for First Quarter 2015 10Isis Reports Financial Results and Highlights for First Quarter 2015 11Isis Reports Financial Results and Highlights for First Quarter 2015 12Isis Reports Financial Results and Highlights for First Quarter 2015 13
(Date:5/6/2015)... TX (PRWEB) May 06, 2015 The ... opened its first freestanding emergency room in Chandler on ... Health Arizona General Hospital, which is also part of ... celebrate the grand opening, Dignity Health Arizona General Hospital ... Chandler Chamber of Commerce and donated $5,000 to Campo ...
(Date:5/6/2015)... London, England (PRWEB) May 06, 2015 ... exploding with new drinks. Little Miracles organic tea and ... by natural Panax ginseng and sweetened with agave, these ... popular consumer movement that seeks healthier ways to hydrate. ... 6, Little Miracles invites people to raise a bottle ...
(Date:5/5/2015)... (PRWEB) May 06, 2015 Social Media ... Make Social Media Your Most Powerful Marketing Tool and ... Washington, DC, http://www.fdanews.com/SocialMedia , Social media … ... of social media’s reach. Patients are using it — ... doctors about what they’ve discovered. , But, it can ...
(Date:5/5/2015)... May 05, 2015 With the FCPX LUT: ... quickly and easily add washed color grades to footage. A ... for modifying an image. The LUT changes every pixel's color ... comes with 90 washed CUBE LUT files. , This plugin ... can give any footage a washed look. , CUBE ...
(Date:5/5/2015)... UAE (PRWEB) May 05, 2015 Private ... , FZ LLC has announced that its dental stem ... for Store-A-Tooth™ increased once again--in April, 2015 –and posted ... month of increased record volume and represents a significant ... Provia’s dental stem cell biobank is conducted via the ...
Breaking Medicine News(10 mins):Health News:Dignity Health and Adeptus Health Opened First Freestanding Emergency Room in Chandler, Arizona 2Health News:Dignity Health and Adeptus Health Opened First Freestanding Emergency Room in Chandler, Arizona 3Health News:Say Cheers to National Beverage Day with Little Miracles 2Health News:FDAnews Announces: Social Media Regulatory Affairs Summit, June 24-26, 2015 2Health News:FDAnews Announces: Social Media Regulatory Affairs Summit, June 24-26, 2015 3Health News:FDAnews Announces: Social Media Regulatory Affairs Summit, June 24-26, 2015 4Health News:Pixel Film Studios Announced the Release of FCPX LUT Monochromatic 2Health News:Grace Century’s Dental Stem Cell Biobank Project Announces Serial Record Enrollment Growth 2Health News:Grace Century’s Dental Stem Cell Biobank Project Announces Serial Record Enrollment Growth 3
... Obama and Secretary of State Clinton on today,s nomination of ... Global AIDS Coordinator (OGAC). AIDS Action is pleased that ... by such an accomplished HIV medical expert with extensive knowledge ... the epidemic here in the United States. We encourage ...
... , Incorporated, a leading provider of business ... services, continues to expand its portfolio of innovative ... RACSource, a financial management and appeals analysis ... SOURCECORP ,s extensive experience in denial management, ...
... Indian Oncologists Are Starting to Embrace Use of ... a Report from Decision Resources WALTHAM, Mass., April ... leading research and advisory firms focusing on pharmaceutical ... brand/generics (oxaliplatin) and Roche/Chugai,s Xeloda, Indian brand/generics (capecitabine) ...
... WASHINGTON, April 28 First quarter federal reports ... provisions of the federal economic stimulus act, contradicting ... report of its effort was "100 percent false."Google,s ... lobbying during the period including on "online health-related ...
... Mich., April 28 Richard E. Smith, M.D., an ... as the 144th president of the Michigan State Medical ... MSMS House of Delegates meeting in Grand Rapids. (Logo: ... first African American to serve as MSMS president, will ...
... university Karolinska Institutet have shown that rapid diagnostic tests ... healthcare in low and mid-income countries in the fight ... a simple blood test and, according to the results, ... receive the right treatment at no extra cost for ...
Cached Medicine News:Health News:AIDS Action Applauds Selection of Dr. Eric Goosby as Global AIDS Coordinator 2Health News:SOURCECORP(R) HealthSERVE Unveils Unique Tool for Healthcare Providers to Support Recovery Audit Contractor (RAC) Program Defense 2Health News:Sanofi-Aventis' and Roche/Chugai's Drugs Will Dominate the Indian Colorectal Cancer Drug Market Through 2013 2Health News:Consumer Watchdog: U.S. Senate Records Reveal Google Inc. Lobbying Campaign on Personal Medical Records Law Despite Internet Giant's Denials 2Health News:Consumer Watchdog: U.S. Senate Records Reveal Google Inc. Lobbying Campaign on Personal Medical Records Law Despite Internet Giant's Denials 3Health News:Richard E. Smith, M.D., Installed as President of Michigan State Medical Society 2Health News:Richard E. Smith, M.D., Installed as President of Michigan State Medical Society 3Health News:Simple blood test proves powerful ally in the fight against malaria 2
... Our ELISA products for autoimmune testing feature ... as well as specific reflex tests including ... Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 and ... includes a full line of products for ...
... ELISA products for autoimmune testing feature single-well ... well as specific reflex tests including dsDNA, ... SS-A (Ro), SS-B (La), Scl-70 and Jo-1. ... a full line of products for Cardiolipins ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: